An investigation for investors in Amgen, Inc. (NASDAQ:AMGN) shares over potential securities laws violations by Amgen, Inc. was announced

San Diego, CA -- (SBWire) -- 10/05/2017 --An investigation for investors of Amgen, Inc. (NASDAQ:AMGN) shares over potential securities laws violations by Amgen, Inc. an was announced.

Investors who purchased shares of Amgen, Inc. (NASDAQ:AMGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amgen, Inc. (NASDAQ:AMGN) concerning whether a series of statements by Amgen, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On May 21, 2017, Amgen, Inc. announced data from data from active-comparator study of EVENITY™ (Romosozumab) in postmenopausal women with osteoporosis. Amgen, Inc disclosed that its osteoporosis medicine Evenity raised concerns about heart safety that will lead to a delay in securing approval in the United States. According to data disclosed by Amgen, Inc., a higher percentage of patients who took the drug suffered serious cardiovascular side effects after a year, compared to those who took an older approved medicine.

Those who purchased shares of Amgen, Inc. (NASDAQ:AMGN) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com